The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.
Nicotine receptor partial agonists for smoking cessation
Open accessAbstract
BACKGROUND: Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials are underway. OBJECTIVES: The primary objective of this review is to assess the efficacy and tolerability of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('varenicline' or 'cytisine' or 'Tabex' or 'nicotine receptor partial agonist') and 'smoking' in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, PsycINFO and CINAHL using MeSH terms and free text, and we contacted authors of trial reports for additional information where necessary. The last search was in October 2006. SELECTION CRITERIA: We included randomized controlled trials which compared the treatment drug with placebo. We also included comparisons with bupropion where available. We excluded trials which did not report a minimum follow-up period of six months from start of treatment. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of participants, the dose and duration of treatment, the outcome measures, the randomization procedure, concealment of allocation, and completeness of follow up. The main outcome measured was abstinence from smoking after at least six months from the beginning of treatment. We used the most rigorous definition of abstinence, and preferred biochemically validated rates where they were reported. Where appropriate we performed meta-analysis using the Mantel-Haenszel fixed-effect model. MAIN RESULTS: We found five trials of varenicline compared with placebo for smoking cessation; three of these also included a bupropion experimental arm. We also found one relapse prevention trial, comparing varenicline with placebo. The six trials covered 4924 participants, 2451 of whom used varenicline. We identified one trial of cytisine (Tabex) for inclusion. The pooled odds ratio (OR) for continuous abstinence at 12 months for varenicline versus placebo was 3.22 (95% confidence interval [CI] 2.43 to 4.27). The pooled OR for varenicline versus bupropion was 1.66 (95% CI 1.28 to 2.16). The main adverse effect of varenicline was nausea, which was mostly at mild to moderate levels and usually subsided over time. The two trials which tested the use of varenicline beyond the 12-week standard regimen found the drug to be well-tolerated and effective during long-term use. The one cytisine trial included in this review found that more participants taking cytisine stopped smoking compared with placebo at two-year follow up, with an OR of 1.77 (95% CI 1.30 to 2.40). AUTHORS' CONCLUSIONS: Varenicline increased the odds of successful long-term smoking cessation approximately threefold compared with pharmacologically unassisted quit attempts. In trials reported so far, more participants quit successfully with varenicline than with bupropion. The effectiveness of varenicline as an aid to relapse prevention has not been clearly established. The main adverse effect of varenciline is nausea, but this is mostly at mild to moderate levels and tends to reduce with habituation. There is a need for independent trials of varenicline versus placebo, to test the early findings. There is also a need for direct comparisons with nicotine replacement therapy, and for further trials with bupropion, to establish the relative efficacy of the treatments.Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Newer, more targeted pharmacotherapies have led to significant improvements in aiding tobacco cessation rates [213].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [213]
In the citing paper
“Two open label, randomized controlled trial were unable to confirm significant improvements with varenicline over NRT in continuous abstinence rates at 52 weeks following short term treatment [213, 242, 243].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [213]
In the citing paper
“The mean quit rate at 6 months across the studies for OTC nicotine replacements was 7%.”
From Tobacco addiction (2008) · cites this paper as [91]
In the citing paper
“similar quit rates were observed between OTC patch and prescription NRTs (OR 1.4, 95% CI 0.6, 3.3).”
From Tobacco addiction (2008) · cites this paper as [91]
In the citing paper
“OTC nicotine patch continued to demonstrate improved efficacy over placebo (OR 2.5, 95% CI 1.8, 3.6)”
From Tobacco addiction (2008) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,564
Self-citationPharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Outcome criteria in smoking cessation trials: proposal for a common standard
West, R., Hajek, P., Stead, L., & Stapleton, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00995.x · Cited by 1,285
Self-citationPharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Self-citation
Flagged first, then by citations
Research works printed but not linked: 13
- Reeves K Watsky E Williams K Azoulay S Billing B Gong J The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54] Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA 2006
- Benndorf, 1968, Results of smoking cessation treatment with cytisin (Tabex®), Das Deutsche Gesundheitwesen, 23, 2092
- Benndorf, 1970, Smoking cessation treatment with cytisin (Tabex®): half-yearly outcomes for former smokers abstinent at four weeks from beginning of treatment, Das Deutsche Gesundheitwesen, 24, 774
- Benndorf, 1969, Further reports on a double blind trial of the Bulgarian cytisine compound Tabex® on 1214 smokers wishing to quit and practical experience in conducting clinics for such smokers, Das Deutsche Gesundheitswesen, 24, 1135
- Scharfenberg, 1971, Cytisine (Tabex®) as a treatment for smoking cessation, Das Deutsche Gesundheitwesen, 26, 463
- Granatowicz, 1976, Smoking cessation through the use of cytisine and other therapy, World Smoking Health, 1, 8
- Bacvarov, 1967, Smoking cessation through medication: remarks on G. Scharfenberg, E Winkelvoss and S. benndorf, Munch Med Wschr. 109 (1967) 1687-1689, Munchener Medizinische Wochenschrift, 109, 2663
- Kempe, 1967, Observation about the Bulgarian medicine for smoking withdrawl Tabex, produced by Pharmachim-Sofia, Savr Med, 18, 355
- Paun, 1968, [Smoking cessation with cytisine 'Tabex' tablets] [German], Sonderduck aus das deutsche Gesundheitwesen, 23, 2088
- Paun, 1970, Tabex: registering and treatment of smokers with chronic bronchitis in the consultation against tobacco smoking - Berlin, Medico-Biologic Information, 3, 15
- Stoyanov, 1972, [On the therapeutic effectiveness and tolerability of Tabex] [Bulgarian], Savremenna Medicina, 23, 30
- Pfizer, An open-label, mullticentre study with follow-up evaluating the safety and efficacy of varenicline tartrate in comparison to transdermal nicotine patch for smoking cessation, www.controlled-trials.com/mRCT/trial/125463 (accessed 21/2/2006), ClinicalTrials.
- Pfizer, A 12-week, double-blind, placebo-controlled, multicenter study with varenicline tartrate 1mg bid for smoking cessation, www.controlled-trials.com/mRCT/trial/123367 (accessed 21/2/2006), ClinicalTrials.
Cited by
Sorted by citations
Items 301–400 of 749
Edelman, E. J., Dziura, J. D., Deng, Y., Bold, K. W., Murphy, S. M., Porter, E., Sigel, K. M., Yager, J. E., Ledgerwood, D. M., & Bernstein, S. L. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106379 · Cited by 29
Selby, P. L., Brosky, G., OH, P. I., Raymond, V., & Ranger, S. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-101 · Cited by 29
Update on pharmacologic and nonpharmacologic therapies for smoking cessation.
Schmelzle, J., Rosser, W., & Birtwhistle, R. (2008) · Europe PMC (PubMed Central) · Cited by 28
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Huang, Y. S., Lewis, S., & Britton, J. R. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-1024 · Cited by 28
Non‐invasive brain stimulation for smoking cessation: a systematic review and meta‐analysis
Petit, B., Dornier, A., Meille, V., Demina, A., & Trojak, B. (2022) · Addiction · doi:10.1111/add.15889 · Cited by 33
Effectiveness of varenicline for smoking cessation: A 1-year follow-up study
Grassi, M., Enea, D., Ferketich, A. K., Lü, B., Pasquariello, S., & Nencini, P. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.01.014 · Cited by 27
Smoking cessation therapy with varenicline
Krishna, G. (2008) · International Journal of COPD · doi:10.2147/copd.s1848 · Cited by 28
West, R., Coyle, K., Owen, L., Coyle, D., Pokhrel, S., & On behalf of the EQUIPT Study Group (2017) · Addiction · doi:10.1111/add.14006 · Cited by 29
Consensus statement on smoking cessation in patients with pain
Iida, H., Yamaguchi, S., Goyagi, T., Sugiyama, Y., Taniguchi, C., Matsubara, T., Yamada, N., Yonekura, H., & Iida, M. (2022) · Journal of Anesthesia · doi:10.1007/s00540-022-03097-w · Cited by 28
Roh, S., Hoeppner, S. S., Schoenfeld, D., Fullerton, C. A., Stoeckel, L. E., & Evins, A. E. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3286-3 · Cited by 28
Verrico, C. D., Mahoney, J. J., Thompson-Lake, D. G. Y., Bennett, R. S., Newton, T. F., & Garza, R. D. L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571300134x · Cited by 26
Concurrent access to nicotine and sucrose in rats
Panlilio, L. V., Hogarth, L., & Shoaib, M. C. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3787-8 · Cited by 26
Interventions for smoking cessation in people diagnosed with lung cancer
Zeng, L., Yu, X., Yu, T., Jianhong, X., & Huang, Y. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011751.pub3 · Cited by 26
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes
Russo, C., Walicka, M., Caponnetto, P., Cibella, F., Maglia, M. G., Alamo, A., Campagna, D., Frittitta, L., Mauro, M. D., Caci, G., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.17709 · Cited by 26
Lotfipour, S., Mandelkern, M. A., Alvarez-Estrada, M., & Brody, A. L. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.20 · Cited by 26
Cheung, K. L., Wijnen, B. F. M., Hiligsmann, M., Coyle, K., Coyle, D., Pokhrel, S., de Vries, H., Präger, M., & Evers, S. (2017) · Addiction · doi:10.1111/add.14069 · Cited by 25
Dogar, O. F., Barua, D., Boeckmann, M., Elsey, H., Fatima, R., Gabe, R., Huque, R., Keding, A., Khan, A., Kotz, D., et al. (2018) · Addiction · doi:10.1111/add.14242 · Cited by 26
Aveyard, P. N., Wang, D., Connock, M. J., Fry-Smith, A., Barton, P. M., & Moore, D. (2009) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntp035 · Cited by 26
Smoking cessation: lessons learned from clinical trial evidence
Reid, R. D., Quinlan, B., Riley, D. L., & Pipe, A. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328236740a · Cited by 26
The role of varenicline on alcohol-primed self-administration and seeking behavior in rats
Randall, P. A., Jaramillo, A. A., Frisbee, S., & Besheer, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3878-1 · Cited by 25
Comparison of monoamine oxidase inhibition by cigarettes and modified risk tobacco products
van der Toorn, M., Koshibu, K., Schlage, W. K., Majeed, S., Pospíšil, P., Hoeng, J., & Peitsch, M. C. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.11.008 · Cited by 25
Tindle, H. A., Freiberg, M. S., Cheng, D. M., Gnatienko, N., Blokhina, E. A., Yaroslavtseva, T. V., Bendiks, S., Patts, G. J., Hahn, J. A., So‐Armah, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.25129 · Cited by 25
Sha, L., Yang, X., Deng, R., Wang, W., Tao, Y., Cao, H.-L., Ma, Q., Wang, H., Nie, Y., Leng, S., et al. (2022) · Journal of Medical Internet Research · doi:10.2196/38206 · Cited by 25
Santi, O. D., Orellana, M., Niro, C. A. D., & Greco, V. (2023) · Addiction · doi:10.1111/add.16399 · Cited by 27
Lindson, N., Aveyard, P. N., Ingram, J. T., Inglis, J., Beach, J., West, R., & Michie, S. (2009) · Trials · doi:10.1186/1745-6215-10-69 · Cited by 27
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., Lancaster, T., & Polônio, I. B. (2012) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802012000500014 · Cited by 25
Self-citationConstitutional mechanisms of vulnerability and resilience to nicotine dependence
Hiroi, N., & Scott, D. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.16 · Cited by 26
Sex differences in the association of cigarette craving with insula structure
Perez Diaz, M., Pochon, J.-B., Ghahremani, D. G., Dean, A. C., Faulkner, P., Petersen, N., Tyndale, R. F., Donis, A., Paez, D., Cahuantzi, C., et al. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab015 · Cited by 24
Update on the approach to smoking in patients with respiratory diseases
Sales, M. P. U., de Araújo, A. J., Chatkin, J. M., Godoy, I., Pereira, L. F. F., Castellano, M. V. C. D. O., Tanni, S. É., de Almeida, A. Á., Chatkin, G., da Silva, L. C. C., et al. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20180314 · Cited by 30
Reddy, K. P., Kruse, G. R., Lee, S., Shuter, J., & Rigotti, N. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1069 · Cited by 24
Javitz, H. S., Zbikowski, S. M., Deprey, M., McAfee, T. A., McClure, J. B., Richards, J. A., Catz, S. L., Jack, L. M., & Swan, G. E. (2010) · Translational Behavioral Medicine · doi:10.1007/s13142-010-0009-8 · Cited by 24
Cost‐effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD
Trapero‐Bertran, M., Muñoz, C., Coyle, K., Coyle, D., Lester‐George, A., Leidl, R., Németh, B., Cheung, K. L., Pokhrel, S., & Nicolás, Á. L. (2018) · Addiction · doi:10.1111/add.14090 · Cited by 23
Cinciripini, P. M., Minnix, J. A., Green, C. E., Robinson, J. D., Engelmann, J. M., Versace, F., Wetter, D. W., Shete, S. S., & Karam‐Hage, M. (2018) · Addiction · doi:10.1111/add.14250 · Cited by 28
Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?
Moore, R. A., & Aubin, H. (2012) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph9010192 · Cited by 24
Anthenelli, R. M., Gaffney, M., Benowitz, N. L., West, R., McRae, T. D., Russ, C., Lawrence, D., Aubin, L. S., Krishen, A., & Evins, A. E. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-04858-2 · Cited by 23
Kim, Y., Lee, J. S., & Cho, W. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041576 · Cited by 24
Enger, C. L., Younus, M., Petronis, K. R., Mo, J., Gately, R. V., & Seeger, J. D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3400 · Cited by 23
Kasza, K. A., Cummings, K. M., Carpenter, M. J., Cornelius, M. E., Hyland, A. J., & Fong, G. T. (2014) · Addiction · doi:10.1111/add.12778 · Cited by 23
Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [11C]-(+)-PHNO PET Study
Ciano, P. D., Guranda, M., Lagzdins, D., Tyndale, R. F., Gamaleddin, I., Selby, P. L., Boileau, I., & Foll, B. L. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.305 · Cited by 23
Hurt, R. T., Croghan, I. T., Schroeder, D. R., Hays, J. T., Choi, D., & Ebbert, J. O. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw304 · Cited by 23
Caponnetto, P., Polosa, R., Robson, D., & Bauld, L. (2020) · Health Psychology Research · doi:10.4081/hpr.2020.9042 · Cited by 24
Xi, Z. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6299 · Cited by 26
Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats
Crunelle, C. L., Schulz, S., de Bruin, K. M., Miller, M. L., van den Brink, W., & Booij, J. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.001 · Cited by 23
Gossec, L., Soubrier, M., Foissac, F., Moltó, A., Richette, P., Beauvais, C., Ruyssen‐Witrand, A., Perdriger, A., Chary-Valckenaere, I., Mouterde, G., et al. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000914 · Cited by 22
Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis
Shang, X., Fenfen, E., Guo, K., Yang, C., Zhou, L., Wu, Y., Yang, K., & Li, X. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001171 · Cited by 22
Brose, L. S., Simonavičius, E., & McNeill, A. D. (2017) · Psychological Medicine · doi:10.1017/s0033291717002021 · Cited by 22
Lesage, E., Sutherland, M. T., Ross, T. J., Salmeron, B. J., & Stein, E. A. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0623-1 · Cited by 25
McCaul, M. E., Wand, G. S., Kuwabara, H., Dannals, R. F., Wong, D. F., & Xu, X. (2019) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz080 · Cited by 24
A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data
Xenakis, J. G., Kinter, E. T., Ishak, K. J., Ward, A. J., Marton, J. P., Willke, R. J., Davies, S., & Jaime, J. (2011) · PharmacoEconomics · doi:10.2165/11589230-000000000-00000 · Cited by 21
Adherence to Tobacco Dependence Treatment Among HIV-Infected Smokers
Browning, K. K., Wewers, M. E., Ferketich, A. K., Diaz, P., Koletar, S. L., & Reynolds, N. R. (2015) · AIDS and Behavior · doi:10.1007/s10461-015-1059-1 · Cited by 22
van Eerd, E. A. M., Risør, M. B., van Rossem, C., van Schayck, O. C. P., & Kotz, D. (2015) · BMC Family Practice · doi:10.1186/s12875-015-0382-y · Cited by 21
Shahab, L., Bauld, L., McNeill, A. D., & Tyndale, R. F. (2018) · Addiction · doi:10.1111/add.14450 · Cited by 21
Thoracic Surgeons’ Beliefs and Practices on Smoking Cessation Before Lung Resection
Marrufo, A. S., Kozower, B. D., Tancredi, D. J., Nuno, M. A., Cooke, D. T., Pollock, B. H., Romano, P. S., & Brown, L. M. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.11.055 · Cited by 21
Electronic Cigarette Cessation in Youth and Young Adults: A Case Series
Sikka, G., Oluyinka, M., Schreiber, R., & Galiatsatos, P. (2021) · Tobacco Use Insights · doi:10.1177/1179173x211026676 · Cited by 21
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Trials · doi:10.1186/s13063-023-07164-9 · Cited by 20
Hsueh, K.-C., Hsueh, S.-C., Chou, M.-Y., Pan, L.-F., Tu, M., McEwen, A., & West, R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3482-9 · Cited by 20
Smoking cessation therapy during pregnancy.
Cressman, A. M., Pupco, A., Kim, E., Koren, G., & Bozzo, P. (2012) · Europe PMC (PubMed Central) · Cited by 20
Joo, H., Cho, M. H., Cho, Y., Joh, H., & Kim, J. W. (2020) · Medicine · doi:10.1097/md.0000000000018994 · Cited by 21
Buczkowski, K., Marcinowicz, L., Czachowski, S., Piszczek, E., & Sowińska, A. (2013) · BMC Family Practice · doi:10.1186/1471-2296-14-159 · Cited by 20
Etter, J. (2009) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.10.021 · Cited by 20
Edjoc, R., Reid, R. D., & Sharma, M. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-002022 · Cited by 20
Priorities for tobacco control research in I ndia
Sarkar, B. K., & Reddy, K. S. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03942.x · Cited by 20
Preventing Relapse Following Smoking Cessation
Collins, S. E., Witkiewitz, K. A., Kirouac, M., & Marlatt, G. A. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0124-6 · Cited by 19
Ti, L., Richardson, L., DeBeck, K., Nguyen, P., Montaner, J., Wood, E., & Kerr, T. H. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.05.003 · Cited by 19
Smoking cessation readiness: Are your patients ready to quit?
Woody, D., DeCristofaro, C., & Carlton, B. G. (2008) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2008.00344.x · Cited by 19
Carson‐Chahhoud, K., Smith, B. J., Peters, M. J., Brinn, M. P., Ameer, F., Singh, K., Fitridge, R., Koblar, S. A., Jannes, J., Veale, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231095 · Cited by 19
Review: Pharmacotherapy for smoking cessation
Carrozzi, L., Pistelli, F., & Viegi, G. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096136 · Cited by 19
Srivastava, A. B., Ramsey, A. T., McIntosh, L. D., Bailey, T. C., Fisher, S. L., Fox, L. W., Castro, M., Ma, Y., Baker, T. B., Chen, L., et al. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty031 · Cited by 19
Berlin, I., Dautzenberg, B., Lehmann, B., Palmyre, J., Liégey, E., Rycke, Y. D., & Tubach, F. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028832 · Cited by 20
Esen, A. D., Soylem, Y., Arica, S. G., Belgin, G., & Gonultas, N. (2020) · Tobacco Prevention & Cessation · doi:10.18332/tpc/130471 · Cited by 19
DEHMER, G. J., Grines, C. L., Bakaeen, F. G., Beasley, D. L., Beckie, T. M., Boyd, J. H., Cigarroa, J. E., Das, S. R., Diekemper, R. L., Frampton, J., et al. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000121 · Cited by 18
R-Modafinil Attenuates Nicotine-Taking and Nicotine-Seeking Behavior in Alcohol-Preferring Rats
Wang, X.-F., Bi, G., He, Y., Yang, H.-J., Gao, J., Bakare, O. M., Slack, R. D., Gardner, E. L., Xi, Z., & Newman, A. H. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.24 · Cited by 18
Exploring the Nicotinic Acetylcholine Receptor-Associated Proteome with iTRAQ and Transgenic Mice
McClure‐Begley, T. D., Stone, K. L., Marks, M. J., Grady, S. R., Colangelo, C. M., Lindstrom, J. M., & Picciotto, M. R. (2013) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2013.05.005 · Cited by 18
Walker, N. K., Howe, C., Bullen, C., McRobbie, H. J., Glover, M., Parag, V., Williman, J. A., Veale, R., Nosa, V. H., & Barnes, J. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-880 · Cited by 18
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline
Schassburger, R. L., Levin, M. E., Weaver, M. T., Palmatier, M. I., Caggiula, A. R., Donny, E. C., & Sved, A. F. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3732-x · Cited by 19
Lindson, N., Coleman, T. J., Docherty, G., Hájek, P., Lewis, S., Lycett, D., McEwen, A., McRobbie, H. J., Munafo, M. R., Parrott, S., et al. (2014) · Trials · doi:10.1186/1745-6215-15-296 · Cited by 18
Littlewood, R. A., Claus, E. D., Wilcox, C. E., Mickey, J., Arenella, P. B., Bryan, A. D., & Hutchison, K. E. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4721-7 · Cited by 19
Evidence for the Efficacy of a Bioresonance Method in Smoking Cessation: A Pilot Study
Pıhtılı, A., Galle, M., Çuhadaroğlu, Ç., Kılıçaslan, Z., İşsever, H., Erkan, F., Çağatay, T., & Gülbaran, Z. (2014) · Complementary Medicine Research · doi:10.1159/000365742 · Cited by 18
Yingst, J. M., Veldheer, S., Hrabovsky, S., Hammett, E., Nicholson, J. M., Berg, A. S., & Foulds, J. (2018) · Journal of Health Communication · doi:10.1080/10810730.2018.1453890 · Cited by 18
Motivational interviewing for smoking cessation
Lai, D. T., Qin, Y., & Tang, J.-L. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006936 · Cited by 18
Biomarkers to Optimize the Treatment of Nicotine Dependence
Schnoll, R. A., & Leone, F. T. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.91 · Cited by 17
Rollema, H., Wilson, G. G., Lee, T. C., Folgering, J. H. A., & Flik, G. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.015 · Cited by 17
How to manage cigarette smoking in kidney transplant candidates and recipients?
Devresse, A., Gohy, S. T., Robert, A., & Kanaan, N. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab072 · Cited by 16
The use of biomarkers to guide precision treatment for tobacco use
Siegel, S. D., Tindle, H. A., Bergen, A. W., Tyndale, R. F., & Schnoll, R. A. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100076 · Cited by 17
McDermott, M. S., West, R., Brose, L. S., & McEwen, A. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.01.003 · Cited by 17
Selby, P. L., Brosky, G., OH, P. I., Raymond, V., Arteaga, C., & Ranger, S. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-433 · Cited by 17
Minding the brain: the role of pharmacotherapy in substance-use disorder treatment
Dakwar, E., & Kleber, H. D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/hkleber · Cited by 17
Patterns of nicotine dependence in four Eastern European countries
Kaleta, D., Polańska, K., Korytkowski, P., Usidame, B., & Bąk‐Romaniszyn, L. (2015) · BMC Public Health · doi:10.1186/s12889-015-2537-0 · Cited by 17
de Dios, M. A., Cano, M. Á., Vaughan, E. L., Childress, S. D., McNeel, M. M., Harvey, L. M., & NIAURA, R. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210323 · Cited by 17
Liu, C., Dong, F., Li, Y., Ren, Y., Xie, D., Wang, X., Xue, T., Zhang, M., Ren, G., von Deneen, K. M., et al. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01814 · Cited by 17
Caponnetto, P. (2020) · Health Psychology Research · doi:10.4081/hpr.2020.9463 · Cited by 16
Smoke and mirrors: The overnight abstinence paradigm as an index of disrupted cognitive function
Rhodes, J. D., & Hawk, L. W. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4227-8 · Cited by 16
DeBaker, M. C., Robinson, J. M., Moen, J. K., Wickman, K. D., & Lee, A. M. (2019) · Alcohol · doi:10.1016/j.alcohol.2019.09.006 · Cited by 16
The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
Khoo, S. Y., McNally, G. P., & Clemens, K. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173967 · Cited by 16
Wang, C., Huang, P., Shen, Z., Qian, W. P., Wang, S., Jiaerken, Y., Luo, X., Li, K., Zeng, Q., Zhou, C., et al. (2020) · Addiction Biology · doi:10.1111/adb.12919 · Cited by 13
Klemperer, E. M., Streck, J. M., Lindson, N., West, J. C., Su, A., Hughes, J. R., & Carpenter, M. J. (2022) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000583 · Cited by 16
Upton, M. K., & Lotfipour, S. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.015 · Cited by 16
Zimovetz, E. A., Wilson, K., Samuel, M., & Beard, S. M. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01439.x · Cited by 15
La importancia de tratar la dependencia tabáquica
McRobbie, H. J., & Thornley, S. (2008) · Revista Española de Cardiología · doi:10.1157/13123068 · Cited by 17
Metadata
- Authors
- Cahill, K., Stead, L., & Lancaster, T.
- Affiliations
- University of Oxford (GB)
- University of Bristol (GB)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2007-01-24
- Issue
- 1
- Pages
- CD006103-CD006103
- ISSN
- 1361-6137 (ISSN-L)
- PMC
- PMC6464943
- OpenAlex
- W2116514043
- Cited by
- 747
- References
- 245
- Citations by year
- 2025: 15 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 41 · 2020: 21 · 2019: 36 · 2018: 33 · 2017: 49 · 2016: 28 · 2015: 41 · 2014: 49 · 2013: 57 · 2012: 68
- Type
- reference entry
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- nicotine receptor partial agonist, smoking cessation, cytisine, varenicline, nicotine replacement therapy, bupropion, nicotine patch, smoking abstinence, nicotine withdrawal symptoms, smoking satisfaction, nicotine dependence, nicotine antagonists
- MeSH terms
- Varenicline, Quinolizidine Alkaloids, Alkaloids, Azocines, Benzazepines, Humans, Nicotine, Quinolizines, Quinoxalines, Randomized Controlled Trials as Topic, Smoking Cessation, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
